- Home
- SCLXW vs KZR Comparison
SCLXW vs KZR Comparison
Compare SCLXW & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLXW
- KZR
- Stock Information
- Founded
- SCLXW N/A
- KZR 2015
- Country
- SCLXW United States
- KZR United States
- Employees
- SCLXW 111
- KZR N/A
- Industry
- SCLXW Biotechnology: Pharmaceutical Preparations
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- SCLXW Health Care
- KZR Health Care
- Exchange
- SCLXW Nasdaq
- KZR Nasdaq
- Market Cap
- SCLXW N/A
- KZR N/A
- IPO Year
- SCLXW N/A
- KZR 2018
- Fundamental
- Price
- SCLXW $0.10
- KZR $4.40
- Analyst Decision
- SCLXW
- KZR Hold
- Analyst Count
- SCLXW 0
- KZR 2
- Target Price
- SCLXW N/A
- KZR $9.00
- AVG Volume (30 Days)
- SCLXW 4.0K
- KZR 42.3K
- Earning Date
- SCLXW 03-07-2025
- KZR 08-12-2025
- Dividend Yield
- SCLXW N/A
- KZR N/A
- EPS Growth
- SCLXW N/A
- KZR N/A
- EPS
- SCLXW N/A
- KZR N/A
- Revenue
- SCLXW $55,152,000.00
- KZR N/A
- Revenue This Year
- SCLXW N/A
- KZR N/A
- Revenue Next Year
- SCLXW N/A
- KZR N/A
- P/E Ratio
- SCLXW N/A
- KZR N/A
- Revenue Growth
- SCLXW 22.02
- KZR N/A
- 52 Week Low
- SCLXW $0.18
- KZR $3.62
- 52 Week High
- SCLXW $0.18
- KZR $9.18
- Technical
- Relative Strength Index (RSI)
- SCLXW N/A
- KZR 50.74
- Support Level
- SCLXW N/A
- KZR $4.24
- Resistance Level
- SCLXW N/A
- KZR $4.80
- Average True Range (ATR)
- SCLXW 0.00
- KZR 0.34
- MACD
- SCLXW 0.00
- KZR 0.00
- Stochastic Oscillator
- SCLXW 0.00
- KZR 40.00
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.